Literature DB >> 29193248

Impact of muscle volume and muscle function decline in patients undergoing surgical resection for hepatocellular carcinoma.

Atsushi Hiraoka1, Yasuhiro Otsuka2, Hideki Kawasaki3, Hirofumi Izumoto1, Hidetaro Ueki1, Shogo Kitahata1, Toshihiko Aibiki1, Tomonari Okudaira1, Hiroka Yamago1, Yuji Miyamoto1, Ryuichiro Iwasaki1, Hideomi Tomida1, Kenichiro Mori1, Hideki Miyata1, Eiji Tsubouchi1, Masato Kishida1, Masashi Hirooka4, Masanori Abe4, Bunzo Matsuura4, Tomoyuki Ninomiya1, Izumi Mori2, Yoichi Hiasa4, Kojiro Michitaka1.   

Abstract

BACKGROUND AND AIM: This study investigated the prognostic impact of muscle volume loss (MVL) and muscle function decline in patients undergoing resection for hepatocellular carcinoma (HCC).
METHODS: This study enrolled 171 naïve HCC patients treated with resection from 2007 to 2015, after excluding those lacking spirometry or computed tomography findings, who had received non-curative treatments, or with restrictive or obstructive lung disorders. The median peak expiratory flow rate (%PEF) was set as the cut-off value for muscle function decline, and MVL was diagnosed using a previously reported value. Clinical backgrounds and prognosis were retrospectively evaluated.
RESULTS: Overall survival rate was lower in the MVL (n = 35) as compared with the non-MVL (n = 136) group (1/3/5-year overall survival rate = 88.2%/81.6%/55.6% vs 91.0%/81.5%/74.8%, respectively; P = 0.0083), while there were no differences regarding hepatic function or tumor burden between the groups. Child-Pugh class B (hazard ratio [HR] 3.510, 95% confidence interval [CI]: 1.558-7.926, P = 0.0025), beyond Milan criteria (HR 1.866, 95%CI: 1.024-3.403, P = 0.042), and presence of MVL (HR 1.896, 95%CI: 1.052-3.416, P = 0.033) were significant prognostic factors. The decreased %PEF group (n = 84) showed a higher rate of postoperative delirium than the others (n = 87) (27.4% vs 11.5%, P = 0.0088). The cut-off values for %PEF and age for postoperative delirium were 63.3% (area under receiver operating characteristic [AUROC] 0.697) and 73 years old (AUROC 0.734), respectively. Delirium was observed in 50.0% (14/28) of patients with both factors, 23.8% (15/63) of those with 1 factor, and 5.0% (4/80) of those without either factor.
CONCLUSION: Muscle volume loss is an independent prognostic factor in HCC patients treated with surgical resection, while advanced age and decreased muscle function might indicate high risk for postoperative delirium.
© 2017 The Authors Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  hepatocellular carcinoma; muscle function; muscle volume loss; peak expiratory flow rate; prognosis; sarcopenia

Mesh:

Year:  2018        PMID: 29193248     DOI: 10.1111/jgh.14058

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  10 in total

1.  Bone Mineral Density as a Risk Factor for Patients Undergoing Surgery for Hepatocellular Carcinoma.

Authors:  Yosuke Miyachi; Toshimi Kaido; Siuan Yao; Hisaya Shirai; Atsushi Kobayashi; Yuhei Hamaguchi; Naoko Kamo; Shintaro Yagi; Shinji Uemoto
Journal:  World J Surg       Date:  2019-03       Impact factor: 3.352

2.  Effect of Changes in Skeletal Muscle Mass on Oncological Outcomes During First-Line Sunitinib Therapy for Metastatic Renal Cell Carcinoma.

Authors:  Hiroki Ishihara; Toshio Takagi; Tsunenori Kondo; Hironori Fukuda; Kazuhiko Yoshida; Junpei Iizuka; Kazunari Tanabe
Journal:  Target Oncol       Date:  2018-12       Impact factor: 4.493

3.  Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.

Authors:  Atsushi Hiraoka; Masaya Kato; Kaori Marui; Taisei Murakami; Kei Onishi; Tomoko Adachi; Junko Matsuoka; Hidetaro Ueki; Takeaki Yoshino; Miho Tsuruta; Toshihiko Aibiki; Tomonari Okudaira; Taira Kuroda; Ryuichiro Iwasaki; Yoshifumi Suga; Hideki Miyata; Tomoyuki Ninomiya; Masashi Hirooka; Masanori Abe; Bunzo Matsuura; Kojiro Michitaka; Yoichi Hiasa
Journal:  Cancer Med       Date:  2021-05-07       Impact factor: 4.452

4.  Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Koichi Takaguchi; Masanori Atsukawa; Ei Itobayashi; Kunihiko Tsuji; Kazuto Tajiri; Masashi Hirooka; Noritomo Shimada; Hiroshi Shibata; Toru Ishikawa; Hironori Ochi; Toshifumi Tada; Hidenori Toyoda; Kazuhiro Nouso; Akemi Tsutsui; Norio Itokawa; Michitaka Imai; Kouji Joko; Yoichi Hiasa; Kojiro Michitaka
Journal:  Cancer Med       Date:  2018-12-21       Impact factor: 4.452

5.  Easy surveillance of muscle volume decline in chronic liver disease patients using finger-circle (yubi-wakka) test.

Authors:  Atsushi Hiraoka; Hirofumi Izumoto; Hidetaro Ueki; Takeaki Yoshino; Toshihiko Aibiki; Tomonari Okudaira; Hiroka Yamago; Yoshifumi Suga; Ryuichiro Iwasaki; Hideomi Tomida; Kenichiro Mori; Hideki Miyata; Eiji Tsubouchi; Masato Kishida; Tomoyuki Ninomiya; Masashi Hirooka; Masanori Abe; Bunzo Matsuura; Yoichi Hiasa; Kojiro Michitaka
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-02-21       Impact factor: 12.910

6.  Impact of Body Composition on the Risk of Hepatocellular Carcinoma Recurrence After Liver Transplantation.

Authors:  Karolina Grąt; Ryszard Pacho; Michał Grąt; Marek Krawczyk; Krzysztof Zieniewicz; Olgierd Rowiński
Journal:  J Clin Med       Date:  2019-10-13       Impact factor: 4.241

7.  Geriatric nutritional risk index as a potential prognostic marker for patients with resectable pancreatic cancer: a single-center, retrospective cohort study.

Authors:  Naotake Funamizu; Akimasa Sakamoto; Takeshi Utsunomiya; Mio Uraoka; Tomoyuki Nagaoka; Miku Iwata; Chihiro Ito; Kei Tamura; Katsunori Sakamoto; Kohei Ogawa; Yasutsugu Takada
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

8.  Impact of Decorin on the Physical Function and Prognosis of Patients with Hepatocellular Carcinoma.

Authors:  Takumi Kawaguchi; Sachiyo Yoshio; Yuzuru Sakamoto; Ryuki Hashida; Shunji Koya; Keisuke Hirota; Dan Nakano; Sakura Yamamura; Takashi Niizeki; Hiroo Matsuse; Takuji Torimura
Journal:  J Clin Med       Date:  2020-03-28       Impact factor: 4.241

9.  Baseline Sarcopenia is Associated with Lack of Response to Therapy, Liver Decompensation and High Mortality in Hepatocellular Carcinoma Patients.

Authors:  Hanaa Badran; Maha Mohammad Elsabaawy; Amr Ragab; Rasha Abdelhafiz Aly; Ayman Alsebaey; Aliaa Sabry
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01

10.  Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting.

Authors:  Atsushi Hiraoka; Takashi Kumada; Kazuya Kariyama; Toshifumi Tada; Joji Tani; Shinya Fukunishi; Masanori Atsukawa; Masashi Hirooka; Kunihiko Tsuji; Toru Ishikawa; Koichi Takaguchi; Ei Itobayashi; Kazuto Tajiri; Noritomo Shimada; Hiroshi Shibata; Hironori Ochi; Kazuhito Kawata; Satoshi Yasuda; Hidenori Toyoda; Hideko Ohama; Kazuhiro Nouso; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Korenobu Hayama; Taeang Arai; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Kojiro Michitaka; Yoichi Hiasa; Masatoshi Kudo
Journal:  J Gastroenterol Hepatol       Date:  2020-11-29       Impact factor: 4.029

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.